Pamidronate and zoledronic acid (bisphosphonates) are a mainstay in the treatment of men with advanced prostate cancer as well as for breast cancer survivors for the prevention of skeletal-related events (SREs). There have been many clinical trials comparing the efficacy and side effect profiles between pamidronate and zoledronic acid among men with advanced prostate cancer. [...]
One of the major problems faced by men on taxotere (chemotherapy) is anemia. Anemia is characterized as a low red blood cell count. It is often the cause of significant fatigue, another major complaint from men on chemotherapy. Aranesp® and Procrit® are both synthetic versions of the naturally occurring hormone, erythropoietin, that stimulates red blood [...]
The Patient Advocate Foundation (PAF), a national non-profit has announced that it has received a substantial contribution which will provide additional funding support for prostate cancer patients through its Co-Pay Relief Program (CPR). […]
Is there any reason to continue hormone therapy (ADT) while I have become castrate resistant and I’m starting chemotherapy? This is a common question that is asked by many of us. The real underlying question we are asking is: I feel so terrible now and I am getting ready to add chemotherapy with all of [...]
There have been a number of studies that have suggested that some common medications will alter prostate-specific antigen (PSA) levels. Researchers from Stanford University School of Medicine, Stanford, CA., investigated the impact of individual and combinations of common medications thought to impact PSA in a large cross-sectional study of the United States population. [...]